#NeuroPharma
🚨 We mapped 4.6M #microbial protein responses to 312 compounds, uncovering 3 distinct functional gut #microbiome states and revealing how neuropharma triggers deep shifts (lower functional redundancy, higher #AMR proteins).

www.biorxiv.org/content/10.1...
Systematic Metaproteomics Mapping Reveals Functional and Ecological Landscapes of Human Gut Microbiota Responses to Therapeutic Drugs
Therapeutic compounds significantly alter the composition of the gut microbiota, yet their functional and ecological impacts, particularly at the protein level, remain largely unexplored. In this stud...
www.biorxiv.org
February 15, 2025 at 2:04 PM
🧠💥 Did you know #Depression may be coded in your #Immune system?😲🔥Our paper shows how #Inflammation+ #Kynurenine 🧬shape the #Brain ! @mdpiopenaccess.bsky.social #DrugDiscovery #MedChem #Oncology #Neuropharma
📖Read more👉 www.mdpi.com/1424-8247/18...
November 12, 2025 at 6:37 AM
I wonder if the HBP used that logic when they sold this same in silico standin for neuropharma. That was pre deep learning, but i wouldn't be surprised. I wonder if they had/what their evidence was.
May 5, 2025 at 6:33 PM
Nose-to-Brain. Yes that is what we were hoping to do at Impel Pharmaceuticals with the Precision Olfactory Delivery device. We likely did too!! See doi.org/10.1111/head...
December 27, 2025 at 5:24 AM
I am sorry and have a huge amount of background anxiety despite being at far less risk from these walking malignancies.

I only know about my own neuropharma journey but maybe you could try a lower dose of an atypical for some stability?
March 19, 2025 at 8:20 PM
I sussed out a drug interaction that was obvious if you knew the mechanisms but wasn't documented anywhere. Put me in the hospital with a bowel ischemia and severe malnutrition. doctors just kept running labs and prescribing vitamins.

my academic background is neuropharma so I had an edge. still.
July 22, 2026 at 5:32 PM
🌙➡️⚡ #Orexins: once “ #Sleep #Peptides,” now unveiled as global controllers of #Behavior, #Metabolism & #Emotion! This Hot Paper Award maps their #Evolution + #Drugs! 💊🧬 @mdpiopenaccess.bsky.social #Neuropharma #HotPaper www.mdpi.com/2227-9059/12...
September 22, 2025 at 5:26 AM
😱 It’s not just #Serotonin 🎯— #Kynurenine metabolites🧬hijack #Synapses !⚡, driving #Despair😔+ #Anxiety 😵‍💫 @mdpiopenaccess.bsky.social #DrugDiscovery #MedChem #Oncology #Neuropharma
See how🧩in our study
www.mdpi.com/1424-8247/18...
September 24, 2025 at 5:29 AM
T-Neuro is developing an Alzheimer’s diagnostic lab test using a novel biomarker upstream of amyloid and tau. 🧪
www.linkedin.com/posts/t-neur...
T-NeuroPharma on LinkedIn: Excited to share this moment captured at the Brain Health Institute at…
Excited to share this moment captured at the Brain Health Institute at UNLV, featuring T-Neuro's co-founder John Chavez, COO Wayne Laslie, and our new…
www.linkedin.com
December 21, 2024 at 2:32 AM
🔥 Small chemical tweaks, big brain effects 😲🧠⚗️ KYNA analogs preserve motor control while reshaping behavior 📚✨ @mdpiopenaccess.bsky.social #Neuroscience #StructureActivity #Neuropharmacology #Schizophrenia #ParkinsonsDisease
👉 Dive into translational neuropharma
doi.org/10.3390/cell...
December 18, 2025 at 8:35 AM
🧠💥 Did you know #Depression may be coded in your #Immune system?😲🔥Our paper shows how #Inflammation+ #Kynurenine 🧬shape the #Brain ! @MDPIOpenAccess @Pharmaceut_MDPI #DrugDiscovery #MedChem #Oncology #Neuropharma
📖Read more👉 www.mdpi.com/1424-8247/18...
October 3, 2025 at 6:19 AM
🧠💊 Shaping mental wellness, one prescription at a time. The psychotropic drug market is vital for emotional balance. 🧘‍♂️
#MentalHealthMatters #NeuroPharma #PsychotropicDrugs #MindHealth

www.marketresearchfuture.com/reports/psyc...
Psychotropic Drugs Market Size, Trends, Growth Report 2034
Psychotropic Drugs Market Size to reach USD 29.30 Billion at 3.50% CAGR by 2034, by driving industry size, share, top company analysis, segments research, trends and forecast report 2025 to 2032.
www.marketresearchfuture.com
June 19, 2025 at 6:11 AM
🧠⚡ BMB-101 advances toward registrational trials after positive phase 2 data in drug-resistant absence seizures & developmental epileptic encephalopathies.

Read more on what’s next: www.neurologylive.com/view/bmb-101...
#Epilepsy #ClinicalTrials #NeuroPharma #RareDisease #DrugDevelopment #Seizures
BMB-101 Heads for Registrational Trials Following Positive Phase 2 Data in Absence Seizures, Developmental Encephalopathies | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.
www.neurologylive.com
January 9, 2026 at 2:12 PM
💻🕹️🌊🎯 #Docking+100 ns #Dynamics=🎮meets 🌊! #Resveratrol🍇+glucuronide buddy snuggled into a hidden MAO-A pocket (not the usual spot 👀)
Plot twist unlocked! 🔓✨ @mdpiopenaccess.bsky.social #MolecularDocking #Neuropharma doi.org/10.3390/biom...
Resveratrol and Its Metabolite as Potential Allosteric Regulators of Monoamine Oxidase A Activity in the Brain and Liver Under Chronic Predator Stress
Background: Resveratrol has been shown to modulate stress-related anxiety by reducing brain monoamine oxidase A (MAO-A) activity. However, the molecular mechanism underlying this neurochemical effect remains unknown. In this study, we employed in silico approaches to investigate the binding affinity of resveratrol and its predominant blood metabolite, resveratrol glucuronide, to specific sites on MAO-A. Methods: For the in silico analysis, we employed molecular docking and molecular dynamics simulations. Within the liver–brain axis, we investigated the role of hepatic MAO-A in the development of anxiety. The activity of whole-brain MAO-A was compared with its activity in specific brain regions, including the amygdala, hippocampus, and prefrontal cortex. Results: Our findings suggest the presence of an allosteric site on the enzyme that accommodates these compounds. Furthermore, in vivo experiments demonstrated that high-dose resveratrol suppresses MAO activity not only in the brain but also in the liver of stress-exposed rats. The in vivo results are interpreted in the context of an allosteric site on MAO-A in both the brain and liver, which may mediate the interaction with resveratrol and its metabolite. Conclusions: The primary outcomes of the study include the identification of the role of hepatic MAO-A in the development of anxiety-like behavior, as well as the determination of resveratrol dose ranges at which it functions as an allosteric modulator of MAO-A activity.
doi.org
June 20, 2025 at 5:20 AM
Despite the neuropharma, I still get acute anxiety about them coming for me 😂 hope I’m low priority, ugh 👀
April 30, 2025 at 8:54 PM
Probióticos, magnesio y vitamina B: por qué es el trío perfecto para retomar la actividad tras las vacaciones
Con la llegada de septiembre y la vuelta a la rutina , muchas personas sienten lo que se conoce como 'síndrome postvacacional', con síntomas como el cansancio, falta de energía, insomnio o incluso ansiedad por anticiparse a todo lo que acarrea volver. Aunque normalmente se toma como algo normal , la ciencia está señalando que todo esto tiene un factor clave que puede marcar la diferencia en cómo afrontamos este periodo: la microbiota intestinal . Según un estudio publicado en Current Neuropharmacology , el equilibrio de nuestras bacterias intestinales no sólo influye en la digestión y en la inmunidad sino también en el estado de ánimo, el sueño y la energía diaria gracias a la conexión intestino-cerebro . Cuando la microbiota está en desequilibrio puede aparecer lo que los expertos llaman neuroinflamación : un fenómeno en el que las toxinas que vienen del intestino llegan al sistema nervioso central, debilitando la barrera protectora del cerebro. Esto significa fatiga mental, una especie de 'niebla' cognitiva y una sensación de agotamiento constante. Natalia Durán, dietista integrativa y especialista en microbiota y enfermedades autoinmunes , explica que cuidar nuestra flora intestinal en esta época es una estrategia para recuperar el bienestar físico y emocional. «Igual que existe el concepto de 'intestino permeable', también hay una barrera protectora en el cerebro que puede volverse permeable cuando hay inflamación intestinal. Cuando esa barrera se debilita, las toxinas e inflamaciones originadas en el intestino pueden alcanzar el sistema nervioso central, generando lo que conocemos como neuroinflamación. Y eso se traduce en menos energía, más fatiga mental y una sensación constante de 'niebla' en el día a día», Natalia Durán Dietista integrativaLas claves para alcanzarlo La evidencia científica señala tres claves para lograrlo: 1. Los probióticos específicos como Lactobacillus helveticus y Bifidobacterium longum, los cuales han demostrado reducir el estrés y mejorar el estado de ánimo en estudios clínicos. 2. Las vitaminas del grupo B , fundamentales para la producción de energía y neurotransmisores, se ven afectadas para su absorción cuando existe disbiosis intestinal, un desequilibrio de la microbiota. 3. Por último, el magnesio bisglicinato , una forma biodisponible de este mineral que favorece el descanso, la regulación nerviosa y la resistencia al estrés. Noticias relacionadas estandar No Paté de caballa y pepino: la original y curiosa receta que sacia, nutre y refresca Catalina Prieto estandar Si En forma con las Gemelas Pin Cuatro ejercicios con mancuernas para fortalecer todos los músculos del cuerpo Gemelas PinEn definitiva, la vuelta al trabajo y a la vida de antes de vacaciones puede ser menos pesada si entendemos que la energía y la claridad mental no sólo depende del descanso o la motivación . Apostar por un buen cuidado, en este caso de la microbiota, es una forma eficazde afrontar esta rutina con mayor vitalidad, equilibrio y bienestar.
www.abc.es
August 31, 2025 at 11:55 PM
🧠💥 Did you know #Depression may be coded in your #Immune system?😲🔥Our paper shows how #Inflammation+ #Kynurenine 🧬shape the #Brain ! @mdpiopenaccess.bsky.social #DrugDiscovery #MedChem #Oncology #Neuropharma
📖 Read more 👉 www.mdpi.com/1424-8247/18...
September 2, 2025 at 6:22 AM
🤔🧪Tiny #Quinoline tweaks→💊⚙️breakthrough #Therapies?🌐 #AI-driven halogenation+esterification=🚀 #Bioavailability&🎯 multitarget action!🔬 @mdpiopenaccess.bsky.social #DrugDiscovery #MedChem #Oncology #Neuropharma
📖 www.mdpi.com/1424-8247/18...
August 19, 2025 at 11:04 AM
Could tweaking #KYNA unlock safer #Schizophrenia & #Parkinson’s treatments?🤔🧠 SZR-73 preserves motor skills🏃‍♂️👍&shows therapeutic promise💥🔬 @mdpiopenaccess.bsky.social #Neuropharma #KYNA #DrugDiscovery
Read & share! www.mdpi.com/2073-4409/14...
August 11, 2025 at 5:30 AM
🤔🧪Tiny #Quinoline tweaks→💊⚙️breakthrough #Therapies?🌐 #AI-driven halogenation+esterification=🚀 #Bioavailability&🎯 multitarget action!🔬 @MDPIOpenAccess @Pharmaceut_MDPI #DrugDiscovery #MedChem #Oncology #Neuropharma
📖 www.mdpi.com/1424-8247/18...
August 8, 2025 at 5:37 AM
🤔🧪🔬💊⚙️🌐What if tiny #Tweaks to $Quinoline scaffolds unlocked breakthrough #Therapies? #AI-driven #Halogenation & #Esterification boost #Bioavailability & #Multitarget action! @mdpiopenaccess.bsky.social #DrugDiscovery #Oncology #Neuropharma
Dive in—read & share! 📖🔁 www.mdpi.com/1424-8247/18...
July 16, 2025 at 5:38 AM
🤔🧪🔬💊⚙️🌐What if tiny #Tweaks to $Quinoline scaffolds unlocked breakthrough #Therapies? #AI-driven #Halogenation & #Esterification boost #Bioavailability & #Multitarget action! @mdpiopenaccess.bsky.social #DrugDiscovery #Oncology #Neuropharma
Dive in—read & share! 📖🔁 www.mdpi.com/1424-8247/18...
July 7, 2025 at 6:09 AM
💻🕹️🌊🎯 #Docking+100 ns #Dynamics=🎮meets 🌊! #Resveratrol🍇+glucuronide buddy snuggled into a hidden MAO-A pocket (not the usual spot 👀)
Plot twist unlocked! 🔓✨ @mdpiopenaccess.bsky.social #MolecularDocking #Neuropharma doi.org/10.3390/biom...
doi.org
June 3, 2025 at 5:37 AM
💻🕹️🌊🎯 #Docking+100 ns #Dynamics=🎮meets 🌊! #Resveratrol🍇+glucuronide buddy snuggled into a hidden MAO-A pocket (not the usual spot 👀)
Plot twist unlocked! 🔓✨ @mdpiopenaccess.bsky.social #MolecularDocking #Neuropharma doi.org/10.3390/biom...
doi.org
May 29, 2025 at 5:46 AM
🧠 Schizophrenia treatment market to hit $13.41 Billion by 2032
📈 CAGR projected at 5.49%
🔗 Read More
#PortugalHealth #NeuroPharma #SchizophreniaAwareness #HealthcareGrowth

www.icrowdpt.com/2025/05/19/m...
Mercado de esquizofrenia definido para atingir US $ 13.41 bilhões, com um CAGR saudável de 5.49% até as previsões de 2032 – iCrowdNewswire Portuguese
www.icrowdpt.com
June 2, 2025 at 12:47 PM